Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- tricitrullinated PAD 4 extra-cellular auto-antibodies R 2 8 17
- Product Overview:
Citrullinated histone H3 (R2 + R8 + R17) (2-22)-biotin peptide is a biotinylated version of tri-citrullinated histone H3, a nuclear protein that interacts with linker DNA regions between nucleosomes to provide nucleosome core structure stabilization.{52742} Histone H3 is subject to citrullination by protein-arginine deiminase 4 (PAD4) at arginine 2 (R2), R8, and R17 during neutrophil extracellular trap formation (NETosis).{18136} Citrullination of histone H3 at these residues reduces the positive charge of histone H3 and leads to decondensed chromatin, which is expelled into the extracellular space when the neutrophil membrane ruptures.{65427,18136} Increased serum levels of histone H3 citrullinated at R2, R8, and R17 have been found in patients with asthma and in septic shock patients where they are positively associated with a sequential organ failure assessment (SOFA) score and poor survival.{65428,65429} Sputum levels of histone H3 citrullinated at R2, R8, and R17 are increased in patients with rheumatoid arthritis, as well as in individuals identified as at risk for developing rheumatoid arthritis based on their seropositivity for IgA anti-citrullinated protein antibodies (ACPAs).{65430} Cayman’s Citrullinated Histone H3 (R2 + R8 + R17) (2-22)-biotin Peptide is intended for use in the detection of autoantibodies against histone H3 citrullinated at R2, R8, and R17.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.